Optimize Access to Orphan Drugs through Innovative Pricing Models, Value-Based Contracts, and RWD-based Stakeholder Engagement
In its 5th year, World Congress’ Rare Disease Market Access Summit examines key strategies to bringing new products to market, interacting with payers, and gaining reimbursement. As the FDA looks to accelerate the approval pathway and clear the backlog of new orphan drug submissions, the pharmaceutical industry is primed to launch therapies for previously untreated diseases. Through guidance from payers, the gatekeepers for market access, and best practices from global-leading manufacturers, those in attendance will learn tactics for optimized commercialization. Over the three days, topics such as innovative pricing models, value-based contracts, and real world data generation will be discussed in order to help your rare disease market access operations.
For the first time ever, join a summit that will bring together four extremely important therapy topics for 2018: Rare Disease, Oncology, Biosimilars, and Cell & Gene Therapy. A day of shared plenary sessions will provide high-level guidance from key stakeholders, such as policy, payers, senior manufacturing executives and more, in order for an enhanced value proposition when launching new products.
Senior Vice President, Global Marketing and Strategy
EMD Serono, a company of MERCK KGaA
Former Vice President, National Medical Director, Pharmaceutical Policy and Strategy